rates. Analysis of SHIFT trial data showed that patients are subject to higher risk of HF hospitalization as they experience more HF hospitalizations, and are subject to higher risk of non-HF CV hospitalization as they experience more CV hospitalizations. The US claims data analysis only estimated the cumulative (1, 2, and ≥ 3) hospitalization rate for HF and non-HF CV hospitalizations. To derive the hospitalization rate specifically for 1, 2, and ≥ 3 hospitalizations based on the cumulative rate from US claims data, the corresponding cumulative rates were estimated in SHIFT and then used to estimate a scaling factor (US claims data rate/SHIFT rate) between the hospitalization rate from US claims data and SHIFT. This scaling factor was then applied to the event rates in Supplemental Table 2 to   3 derive the hospitalization rate for 1, 2, and ≥ 3 hospitalizations for US claims data. To minimize the risk of overestimating hospitalization rates using US claims data, the rate was capped at the highest rate reported in SHIFT (2.01).
CI indicates confidence interval; CV, cardiovascular; HF, heart failure; and SHIFT, Systolic
Heart failure treatment with the I f inhibitor ivabradine Trial. CV indicates cardiovascular; EQ-5D, EuroQol-5D; HF, heart failure; SE, standard error; and SHIFT, Systolic Heart failure treatment with the I f inhibitor ivabradine Trial.
